AN OVERVIEW OF THE RARE INFECTION MUCORMICOSIS WHICH COMES TO THE AGENDA DURING COVID-19 OUTBREAK

Year 2023, Volume: 2 Issue: 3, 165 - 168, 25.09.2023

Yeliz Özen

https://doi.org/10.57221/izmirtip.1280676

Abstract

Keywords

mucormycosis, antifungal, liposomal amphotericin B

COVİD-19 Salgınında Gündeme Gelen Nadir Enfeksiyon Mukormikoza Genel Bir Bakış

Abstract

Mukormikoz özellikle immunkompromize hasta grubunda çeşitli klinik tablolara yol açan akut seyirli ve mortalitesi yüksek fırsatçı bir enfeksiyondur. İnvaziv fungal enfeksiyonlar içinde aspergillus ve candida enfeksiyonlarından sonra üçüncü sırada yer alır. Covid-19 salgını sırasında Hindistan’da ani artış gösteren ve endişe yaratan mukormikoz vakaları hastalığın tedavisinde uygulanan immunsupresif tedavilerle ilişkilendirilmiş, Covid-19 vakalarında prevelansı %0,3-%0,8 saptanmıştır.Mukormikozun tanı ve tedavisinde, ilerlemelere rağmen mortalite halen oldukça yüksek (%40-80) olup riskli hasta gruplarında, mukormikozun akılda tutulması erken tanı için önemlidir.

Keywords

mukormikoz, antifungal, liposomal amfoterisin B, posakonazol

References

• Kaynaklar 1.Kauffman CA, Malani AN. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep 2007; 9:435.
• 2.Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3:543-52.
• 3.Kontoyiannis DP, Lewis RE. Agents of mucormycosis and Entomophthoramycosis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 9th ed.New York, USA: Churchill Livingstone; 2019. P.3117-3130.
• 4.Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.
• 5.Gale GR, Welch AM. Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum. Am J Med Sci. 1961;241:604-12.
• 6.Shinde RV, Karande GS, Mohite ST, Patil SR. Rhino-orbital mucormycosis in diabetes mellitus. J Clin Diagn Res. 2013;7:1145-7
• 7.McNulty JS. Rhino-cerebral mucormycosis: predisposing factors. Laryngoscope. 1982;92:1140-3.
• 8.Manjunath KS, Shivaswamy S, Kulkarni JD, Kenkare Venkatachalaiah R. Rhino-orbito-cerebral mucormycosis (ROCM) with internal carotid artery stenosis in a diabetic patient with caries tooth and oroantral fistula. BJR Case Rep. 2016 ;2:20150447
• 9.Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044-50.
• 10.Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52:1144-55
• 11.Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60-6.
• 12.Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. AJR Am J Roentgenol. 1985;145:739-41
• 13.Didehdar, M., Moradabadi A, Anoushirvani AA, Tabaeian SP, Yousefimashouf M, Shariati A. Gastrointestinal mucormycosis: a periodic systematic review of case reports from 2015 to 2021. Microbial Pathogenesis, 2022;163:105388
• 14.Kato H, Foster CM, Karri K. Incidence, predisposing conditions and outcomes of cutaneous mucormycosis: a national database study. Mycoses, 2021;64:569-72.
• 15.Levy E, Bia MJ. Isolated renal mucormycosis: case report and review. J Am Soc Nephrol. 1995;5:2014-9.
• 16.Hopkins RJ, Rothman M, Fiore A, Goldblum SE. Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis. 1994;19:1133-7.
• 17.Siddiqi SU, Freedman JD. Isolated central nervous system mucormycosis. South Med J. 1994;87:997-1000.
• 18.Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.
• 19.Machouart M, Larché J, Burton K, Collomb J, Maurer P, Cintrat A, et al. Genetic identification of the main opportunistic Mucorales by PCR-restriction fragment length polymorphism. J Clin Microbiol. 2006;44:805-10.
• 20.Schrödl W, Heydel T, Schwartze VU, Hoffmann K, Grosse-Herrenthey A, Walther G, et al. Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorptionionization-time of flight analyzer-mediated mass spectrometry. J Clin Microbiol. 2012;50:419-27.
• 21.Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline forthe diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405-21.
• 22.Levy E, Bia MJ. Isolated renal mucormycosis: case report and review. J Am Soc Nephrol. 1995;5:2014-9.
• 23.Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, Pangal E, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn J Ophthalmol. 2021;65:515-25.
• 24.Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49:721-7.
• 25.Ramadorai A, Ravi P, Narayanan V. Rhino-cerebral mucormycosis: a prospective analysis of an effective treatment protocol. Ann Maxillofac Surg. 2019;9:192-6
• 26.Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216-24.